Skip to main content
. 2023 Jun 15;15(6):959–972. doi: 10.4251/wjgo.v15.i6.959

Figure 2.

Figure 2

Targeted therapies used in systemic treatment for biliary tract cancers. AKT: Protein kinase B; EGFR: Epidermal growth factor receptor; ERK: Extracellular signal-related kinase; FGFR: Fibroblast growth factor receptor; GTP: Guanosine triphosphate; IDH1: Isocitrate dehydrogenase 1; IDH2: Isocitrate dehydrogenase 2; MEK: Mitogen-activated protein kinase; mTOR: Mammalian target of rapamycin; NTRK: Neurotrophic tyrosine receptor kinase; PI3K: Phosphoinositide-3-kinase; PKD1: Polycystic kidney disease 1; RAF: Raf proto-oncogene; RAS: RAS proto-oncogene.